HD vs PFE: Which Is the Better Buy?

Side-by-side comparison of The Home Depot, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-13.
The Home Depot, Inc. · Consumer Cyclical
$343.30
+34.6% upside to fair value
Grade A High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
HD has more upside to fair value (+34.6%). PFE trades at a lower forward P/E (19.2x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric HD PFE
Current Price $343.30 $25.22
Fair Value Estimate $462.14 $25.92
Upside to Fair Value +34.6% +2.8%
Market Cap $342.3B $143.7B
Forward P/E 24.3x 19.2x
EV / EBITDA 16.5x 12.3x
Price / Sales 2.0x 2.3x
Price / FCF 23.9x 15.2x
Revenue Growth YoY +4.8% +5.4%
Gross Margin 33.1% 69.3%
Operating Margin 12.4% 23.4%
Return on Equity 113.3% 8.4%
Dividend Yield 0% 0%
FCF Yield 4.18% 6.6%
Analyst Consensus Buy Hold
Investment Thesis
HD — The Home Depot, Inc.
The Home Depot, Inc. operates as a leading home improvement retailer in the consumer cyclical sector, leveraging a strong brand and cost advantages to maintain a durable competitive moat. Despite a modest revenue growth of 4.8% and a decline in earnings by 4.2% in the most recent quarter, the company exhibits exceptional profitability metrics including a 113.3% return on equity and solid margins …
PFE — Pfizer Inc.
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
Metric HD PFE
Zone Low $346.61 $19.44
Zone High $392.82 $22.03
In Buy Zone? Yes No
← HD Research    PFE Research →    All Research